Cargando…
Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3–5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial()
BACKGROUND: Outcomes for patients with high-risk diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP chemotherapy are suboptimal but, to date, no alternative regimen has been shown to improve survival rates. This phase 2 trial aimed to assess the efficacy of a Burkitt-like approach for high-ri...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487775/ https://www.ncbi.nlm.nih.gov/pubmed/32464282 http://dx.doi.org/10.1016/j.annonc.2020.05.016 |
_version_ | 1783581557649309696 |
---|---|
author | McMillan, A.K. Phillips, E.H. Kirkwood, A.A. Barrans, S. Burton, C. Rule, S. Patmore, R. Pettengell, R. Ardeshna, K.M. Lawrie, A. Montoto, S. Paneesha, S. Clifton-Hadley, L. Linch, D.C. |
author_facet | McMillan, A.K. Phillips, E.H. Kirkwood, A.A. Barrans, S. Burton, C. Rule, S. Patmore, R. Pettengell, R. Ardeshna, K.M. Lawrie, A. Montoto, S. Paneesha, S. Clifton-Hadley, L. Linch, D.C. |
author_sort | McMillan, A.K. |
collection | PubMed |
description | BACKGROUND: Outcomes for patients with high-risk diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP chemotherapy are suboptimal but, to date, no alternative regimen has been shown to improve survival rates. This phase 2 trial aimed to assess the efficacy of a Burkitt-like approach for high-risk DLBCL using the dose-intense R-CODOX-M/R-IVAC regimen. PATIENTS AND METHODS: Eligible patients were aged 18–65 years with stage II–IV untreated DLBCL and an International Prognostic Index (IPI) score of 3–5. Patients received alternating cycles of CODOX-M (cyclophosphamide, vincristine, doxorubicin and high-dose methotrexate) alternating with IVAC chemotherapy (ifosfamide, etoposide and high-dose cytarabine) plus eight doses of rituximab. Response was assessed by computed tomography after completing all four cycles of chemotherapy. The primary end point was 2-year progression-free survival (PFS). RESULTS: A total of 111 eligible patients were registered; median age was 50 years, IPI score was 3 (60.4%) or 4/5 (39.6%), 54% had a performance status ≥2 and 9% had central nervous system involvement. A total of 85 patients (76.6%) completed all four cycles of chemotherapy. There were five treatment-related deaths (4.3%), all in patients with performance status of 3 and aged >50 years. Two-year PFS for the whole cohort was 67.9% [90% confidence interval (CI) 59.9–74.6] and 2-year overall survival was 76.0% (90% CI 68.5–82.0). The ability to tolerate and complete treatment was lower in patients with performance status ≥2 who were aged >50 years, where 2-year PFS was 43.5% (90% CI 27.9–58.0). CONCLUSIONS: This trial demonstrates that R-CODOX-M/R-IVAC is a feasible and effective regimen for the treatment of younger and/or fit patients with high-risk DLBCL. These encouraging survival rates demonstrate that this regimen warrants further investigation against standard of care. TRIAL REGISTRATION: ClinicalTrials.gov (NCT00974792) and EudraCT (2005-003479-19). |
format | Online Article Text |
id | pubmed-7487775 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-74877752020-09-18 Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3–5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial() McMillan, A.K. Phillips, E.H. Kirkwood, A.A. Barrans, S. Burton, C. Rule, S. Patmore, R. Pettengell, R. Ardeshna, K.M. Lawrie, A. Montoto, S. Paneesha, S. Clifton-Hadley, L. Linch, D.C. Ann Oncol Original Article BACKGROUND: Outcomes for patients with high-risk diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP chemotherapy are suboptimal but, to date, no alternative regimen has been shown to improve survival rates. This phase 2 trial aimed to assess the efficacy of a Burkitt-like approach for high-risk DLBCL using the dose-intense R-CODOX-M/R-IVAC regimen. PATIENTS AND METHODS: Eligible patients were aged 18–65 years with stage II–IV untreated DLBCL and an International Prognostic Index (IPI) score of 3–5. Patients received alternating cycles of CODOX-M (cyclophosphamide, vincristine, doxorubicin and high-dose methotrexate) alternating with IVAC chemotherapy (ifosfamide, etoposide and high-dose cytarabine) plus eight doses of rituximab. Response was assessed by computed tomography after completing all four cycles of chemotherapy. The primary end point was 2-year progression-free survival (PFS). RESULTS: A total of 111 eligible patients were registered; median age was 50 years, IPI score was 3 (60.4%) or 4/5 (39.6%), 54% had a performance status ≥2 and 9% had central nervous system involvement. A total of 85 patients (76.6%) completed all four cycles of chemotherapy. There were five treatment-related deaths (4.3%), all in patients with performance status of 3 and aged >50 years. Two-year PFS for the whole cohort was 67.9% [90% confidence interval (CI) 59.9–74.6] and 2-year overall survival was 76.0% (90% CI 68.5–82.0). The ability to tolerate and complete treatment was lower in patients with performance status ≥2 who were aged >50 years, where 2-year PFS was 43.5% (90% CI 27.9–58.0). CONCLUSIONS: This trial demonstrates that R-CODOX-M/R-IVAC is a feasible and effective regimen for the treatment of younger and/or fit patients with high-risk DLBCL. These encouraging survival rates demonstrate that this regimen warrants further investigation against standard of care. TRIAL REGISTRATION: ClinicalTrials.gov (NCT00974792) and EudraCT (2005-003479-19). Oxford University Press 2020-09 /pmc/articles/PMC7487775/ /pubmed/32464282 http://dx.doi.org/10.1016/j.annonc.2020.05.016 Text en © 2020 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Original Article McMillan, A.K. Phillips, E.H. Kirkwood, A.A. Barrans, S. Burton, C. Rule, S. Patmore, R. Pettengell, R. Ardeshna, K.M. Lawrie, A. Montoto, S. Paneesha, S. Clifton-Hadley, L. Linch, D.C. Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3–5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial() |
title | Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3–5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial() |
title_full | Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3–5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial() |
title_fullStr | Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3–5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial() |
title_full_unstemmed | Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3–5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial() |
title_short | Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3–5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial() |
title_sort | favourable outcomes for high-risk diffuse large b-cell lymphoma (ipi 3–5) treated with front-line r-codox-m/r-ivac chemotherapy: results of a phase 2 uk ncri trial() |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487775/ https://www.ncbi.nlm.nih.gov/pubmed/32464282 http://dx.doi.org/10.1016/j.annonc.2020.05.016 |
work_keys_str_mv | AT mcmillanak favourableoutcomesforhighriskdiffuselargebcelllymphomaipi35treatedwithfrontlinercodoxmrivacchemotherapyresultsofaphase2ukncritrial AT phillipseh favourableoutcomesforhighriskdiffuselargebcelllymphomaipi35treatedwithfrontlinercodoxmrivacchemotherapyresultsofaphase2ukncritrial AT kirkwoodaa favourableoutcomesforhighriskdiffuselargebcelllymphomaipi35treatedwithfrontlinercodoxmrivacchemotherapyresultsofaphase2ukncritrial AT barranss favourableoutcomesforhighriskdiffuselargebcelllymphomaipi35treatedwithfrontlinercodoxmrivacchemotherapyresultsofaphase2ukncritrial AT burtonc favourableoutcomesforhighriskdiffuselargebcelllymphomaipi35treatedwithfrontlinercodoxmrivacchemotherapyresultsofaphase2ukncritrial AT rules favourableoutcomesforhighriskdiffuselargebcelllymphomaipi35treatedwithfrontlinercodoxmrivacchemotherapyresultsofaphase2ukncritrial AT patmorer favourableoutcomesforhighriskdiffuselargebcelllymphomaipi35treatedwithfrontlinercodoxmrivacchemotherapyresultsofaphase2ukncritrial AT pettengellr favourableoutcomesforhighriskdiffuselargebcelllymphomaipi35treatedwithfrontlinercodoxmrivacchemotherapyresultsofaphase2ukncritrial AT ardeshnakm favourableoutcomesforhighriskdiffuselargebcelllymphomaipi35treatedwithfrontlinercodoxmrivacchemotherapyresultsofaphase2ukncritrial AT lawriea favourableoutcomesforhighriskdiffuselargebcelllymphomaipi35treatedwithfrontlinercodoxmrivacchemotherapyresultsofaphase2ukncritrial AT montotos favourableoutcomesforhighriskdiffuselargebcelllymphomaipi35treatedwithfrontlinercodoxmrivacchemotherapyresultsofaphase2ukncritrial AT paneeshas favourableoutcomesforhighriskdiffuselargebcelllymphomaipi35treatedwithfrontlinercodoxmrivacchemotherapyresultsofaphase2ukncritrial AT cliftonhadleyl favourableoutcomesforhighriskdiffuselargebcelllymphomaipi35treatedwithfrontlinercodoxmrivacchemotherapyresultsofaphase2ukncritrial AT linchdc favourableoutcomesforhighriskdiffuselargebcelllymphomaipi35treatedwithfrontlinercodoxmrivacchemotherapyresultsofaphase2ukncritrial |